Dual GLP-1/GIP Receptor Agonist Shows Decreases in Hemoglobin A1c
Drug Topics
AUGUST 7, 2025
Since their debut, these novel agents have formed an important armamentarium in the management of T2DM,” authors of a review published in Diabetes, Metabolic Syndrome, and Obesity said. GLP-1/GIPs have shown favorable outcomes in diabetes, significantly improving hemoglobin A 1c , which varies by therapeutic agent.
Let's personalize your content